Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

114.19 +3.69 (+3.34%)
Streaming Delayed Price Updated: 1:37 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money. 
Via The Motley Fool
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
The company is working to treat Duchenne muscular dystrophy, a muscle-wasting disease. 
Via Investor's Business Daily
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
From Sarepta Therapeutics, Inc.
Via Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Why Sarepta Therapeutics Stock Is Skyrocketing Today
Investors are cheering a key FDA advisory committee vote. 
Via The Motley Fool
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock. 
Via MarketBeat
Exposures Product Safety
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
Why Sarepta Therapeutics Stock Faded This Week
The biotech's shares have turned volatile ahead of an important regulatory event. 
Via The Motley Fool
Sarepta: The AdCom Documents Enter The Discussion
The AdCom documents are going to stimulate a robust discussion about the upcoming vote. 
Via Talk Markets
Expert Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics Earnings Preview
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Sarepta (SRPT) Stock Up 29% Today?
Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy. 
Via InvestorPlace
Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday in favor of the company's DMD gene therapy for accelerated approval in... 
Via Benzinga
US Stocks Mixed; NY Manufacturing Activity Shrinks In May
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 75 points on Monday. Following the market opening Monday, the Dow traded down 0.23% to 33,224.02 while the NASDAQ rose 0.18% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 15, 2023: TSLA, SRPT, TJX, MNDY, LTRY
Tesla (TSLA) - The company will host its annual shareholder meeting on Tuesday. The event will be broadcast on YouTube and begins at 4 p.m. EDT. A reminder that annual shareholder meetings are 
Via Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher Monday after the company announced the FDA voted in favor of its gene therapy to treat Duchenne muscular dystrophy late... 
Via Benzinga
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene... 
Via Benzinga
2 Supercharged Growth Stocks to Buy Right Now
These two biopharma stocks might be poised for a major breakout. 
Via The Motley Fool
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy
The gene therapy would treat Duchenne muscular dystrophy, a muscle-wasting disease. 
Via Investor's Business Daily
FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee is meeting this Friday to discuss Sarepta Therapeutics Inc's (NASDAQ: SRPT) to review SRP-9001 (delandistrogene moxeparvovec),... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.